Clearside Biomedical Announces Pricing of $15 Million Registered Direct OfferingGlobeNewsWire • 02/07/24
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMDGlobeNewsWire • 12/14/23
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare ConferenceGlobeNewsWire • 11/08/23
Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual MeetingGlobeNewsWire • 11/07/23
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingGlobeNewsWire • 11/02/23
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMDGlobeNewsWire • 11/01/23
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023GlobeNewsWire • 10/31/23
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific MeetingGlobeNewsWire • 10/16/23
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in ChinaGlobeNewsWire • 10/04/23
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare SummitGlobeNewsWire • 10/03/23
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceGlobeNewsWire • 09/19/23
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023GlobeNewsWire • 08/02/23
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023GlobeNewsWire • 08/01/23
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific MeetingGlobeNewsWire • 07/31/23
Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific MeetingsGlobeNewsWire • 07/20/23
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMDGlobeNewsWire • 07/17/23
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023GlobeNewsWire • 07/11/23
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular EdemaGlobeNewsWire • 07/10/23
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMDGlobeNewsWire • 06/01/23
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23